Spectrum Pharmaceuticals announced full enrollment of cohort 1 for previously treated Non-Small Cell Lung Cancer, or NSCLC, patients with EGFR exon 20 insertion mutations with sites across the U.S., Europe, and Canada. The EGFR previously treated cohort is part of the ZENITH20 trial – an open-label, multi-center, global Phase 2 trial evaluating NSCLC patients with EGFR or HER2 exon 20 insertion mutations. Results from this cohort are expected by the second half of 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.